Skip to main content
Fig. 1 | Trials

Fig. 1

From: An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial

Fig. 1

NeoVanc flow chart demonstrating how the pre-clinical studies, NeoVanc-1 (hollow fibre infection and rabbit models) and NeoVanc-2 (population pharmacokinetics meta-analysis) advised the dosing for the optimised arm of the NeoVanc Clinical Trial (NeoVanc-3)

Back to article page

Trials

ISSN: 1745-6215